Evaluation of thrombogenicity of beta-propiolactone/ultraviolet (beta-PL/UV) treated PPSB in chimpanzees.
The thrombogenicity of beta-PL/UV-treated PPSB (factor IX concentrate) was evaluated in chimpanzees. PPSB isolated from beta-propiolactone-treated and UV-irradiated plasma was injected into chimpanzees at a dose of approximately 100 units/kg body weight. An FDA licensed PPSB preparation served as the negative control, and a preparation containing activated as well as precursor clotting factors served as the positive control. 15 minutes, 1 h, 4 h, and 24 h after the PPSB application the following parameters were determined in the chimpanzee blood: factors II, VII, IX, X, VIII, fibrinogen, AT III, thrombin coagulase, Quick value, APTT and platelet count. Neither the untreated control preparation, nor the PPSB isolated from beta-propiolactone-treated and UV-irradiated plasma, showed signs of thrombogenicity in the chimpanzee model. The positive control indicated that the chimpanzee is a suitable model for the thrombogenicity testing of activated clotting factors.
D000818:Animals; D005164:Factor IX / Q000528:radiation effects*; D005260:Female; D007783:Lactones / Q000009:adverse effects*; D008297:Male; D002679:Pan troglodytes; D011420:Propiolactone / Q000009:adverse effects*; D013927:Thrombosis / Q000209:etiology*; D014466:Ultraviolet Rays / Q000009:adverse effects*
D007783:Lactones; D011420:Propiolactone; D005164:Factor IX